Raymond James Financial
CTMX icon

Raymond James Financial’s CytomX Therapeutics CTMX Stock Holding History

Raymond James Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Buy
484,222
+104,062
+27% +$397K ﹤0.01% 3556
2026
Q1 		$1.79M Buy
380,160
+63,189
+20% +$321K ﹤0.01% 3441
2025
Q4 		$1.35M Buy
316,971
+23,411
+8% +$88.9K ﹤0.01% 3582
2025
Q3 		$936K Buy
293,560
+10,000
+4% +$22.5K ﹤0.01% 3722
2025
Q2 		$644K Buy
+283,560
New +$457K ﹤0.01% 3846

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Raymond James Financial's CTMX Position: Q2 2026 in Review

Raymond James Financial increased its CytomX Therapeutics (CTMX) stake by 27% in Q2 2026, buying an estimated $397K and bringing the position to 484,222 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3556.

Raymond James Financial first reported a position in CTMX in Q2 2025 and has held it in 5 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Raymond James Financial held 484,222 shares of CytomX Therapeutics worth $1.82M as of Q2 2026.
  • Raymond James Financial bought 104,062 CytomX Therapeutics shares in Q2 2026, an estimated $397K.
  • CytomX Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3556 holding.
  • Raymond James Financial first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.